Abstract
Introduction: In 2018, the United States (US) achieved the lowest prevalence of active cigarette smoking since tracking began in 1965 at 13.8%. One factor that has influenced the decline in smoking is the advancement of pharmacotherapeutic treatments targeting the nicotine addiction component of tobacco dependence, specifically varenicline. However, it is unclear if the success of varenicline is evident in all diverse populations. We conducted a systematic review to evaluate the efficacy of varenicline based on race, specifically on Black/African Americans, with regards to smoking cessation.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
